Clinical Trial Update: Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma [Phase 1, Phase 2]

View source ↗

Summary

The clinical trial evaluating interstitial infusion of IL13-PE38QQR cytotoxin in recurrent malignant glioma has completed Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma
• Malignant Glioma
• Oligoastrocytoma

Drugs mentioned

• IL13-PE38QQR cytotoxin (IL13-PE38QQR (interleukin-13 fused to Pseudomonas exotoxin PE38QQR))

Snippet

Sponsor: INSYS Therapeutics Inc | Conditions: Malignant Glioma, Glioblastoma Multiforme | Phase 1, Phase 2 | Status: COMPLETED